Revenue

A key regulatory step for Hadron Energy's micro-reactor, backed by a unique SPAC model, signals a high-stakes bet on the future of U.S. energy.

FBI data shows most active threats begin outdoors. New tech is extending security beyond the building, creating an integrated, automated defense.

After crossing $1B in assets, a community bank adds a healthcare PE expert to its board. This is more than a hire—it's a new strategy for growth.

In a stunning strategic shift, Transcontinental sells its largest division to ProAmpac, rewarding shareholders and refocusing on its printing roots.

Vyome's positive Phase 2 data targets a silent suffering in cancer care. This analysis explores its strategy to dominate a potential $1 billion market.

A deepening corporate governance battle pits STAAR Surgical's board against its largest shareholder and all major proxy firms over a $1.5B Alcon deal.

SAB Biotherapeutics' novel T1D therapy shows promise with a unique safety profile, challenging the status quo and offering new hope for patients.

Onex cashes out of Ryan Specialty with a stunning 49% IRR. We dive into the strategy behind the $1.2B exit and what it signals for specialty insurance.

EyeYon Medical's synthetic corneal implant, EndoArt, just got FDA approval for U.S. trials, offering a fix for the global donor tissue shortage.

As CEO J.K. Symancyk prepares for a key investor conference, Signet Jewelers' new strategy faces the test of a market transformed by tech and ethics.

ATI Inc. names operational veteran Rob Foster as its new CFO, signaling a strategic bet that manufacturing prowess is the key to financial success.

For 14 straight years, Hamilton Lane has been a 'Best Place to Work.' We analyze why this cultural consistency is its most potent strategic asset.

Drone Nerds' new partnership with Creality is more than a product expansion. It's a strategic move by parent XTI Aerospace into digital fabrication.

A new Solana meme coin is turning failure into a feature, offering tokens to traders for their verified losses. Is it a gimmick or the future of engagement?

With advanced ZK tech and a key exchange partnership, Mantle is positioning itself as the institutional-grade bridge between Wall Street and tokenized assets.

A new 31-strain vaccine enters final trials, threatening to upend the market and offer unprecedented protection against a persistent bacterial threat.

A record-breaking tech award reveals a new map of global opportunity, data-driven trends, and a masterclass in strategic brand building from inDrive.

Amid a CEO change, Sherritt International faces a pivotal moment. Can a new leader steer its vital nickel and cobalt assets through volatile markets?

The future of boating isn't just in showrooms. It's in garages where DIYers are driving a quiet, clean-energy revolution on the water. Here's how.

Newron launches a pivotal US trial for its novel schizophrenia drug, evenamide, aiming to help millions who don't respond to current treatments.